« Return to News | Study Conduct

The Medicines Company discontinues phase IIb trial

Friday, October 5, 2012 02:27 PM

The Medicines Company has voluntarily discontinued its phase Iib, dose-ranging study of MDCO-2010, a serine protease inhibitor being developed to reduce blood loss during surgery. This action was taken in response to serious unexpected patient safety issues encountered during the trial, which so far had recruited 44 of a planned 90 patients in the first stage of the study.

While the cause of the safety issues and any potential link to the study drug are still under investigation, the company decided to end both the trial and further development of MDCO-2010 because of the evidence of risk to patients. The Company is conducting an in-depth assessment of all patient data from the study and any information related to drivers of risk. Once this evaluation is completed and reviewed with experts in the field, the findings will be published.

The company has informed regulatory agencies in Germany and in Switzerland, where patients had been enrolled into the study. In addition, the company has informed Health Canada and the FDA, since patient enrollment was planned in both countries. The company will work with regulatory authorities as further information becomes available.

The dose-ranging study was the only clinical trial of MDCO-2010 currently underway. A prior phase IIa trial met its clinical objectives, with results reported in October 2011.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

May 13

New partnership of Parkinson's groups aims to unify the message about importance of trial participation

Using study startup checklists can improve site-sponsor communication, relationships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

INC Research, PPD, inVentiv named top CROs
Yet most CROs slipping in ability to manage site relationships

R&D cuts by sponsors spur more collaboration, innovation
New strategies share pipeline activity costs

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

20 innovators changing the face of the clinical trials industry
The CenterWatch Monthly honors individuals, teams and companies for their forward-thinking ideas and their ability to implement them.

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.